Clinical trials: Advanced Rectal Cancers
Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC), Neoadjuvant Therapy
- Trial name
- NCT07243938
- Testing
- short-course radiotherapy, Zanidatamab, Tisleizumab(BGB-A317)
- Volunteers
- 70 people
- Sponsor
- Tao Zhang
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
To investigate the efficacy and safety of short-course radiotherapy sequential fruquintinib in combination with adebrelimab and CAPOX (full course neoadjuvant therapy) in patients with locally advanced rectal cancer.
- Trial name
- NCT06234007
- Testing
- Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rectal Carcinoma
IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment
RATIONALE: Using small radiation beamlets of different intensity, IMRT (intensity modulated radiation therapy) allows shaping the dose around planning target volume with better sparing of normal tissue comparing to 3D conformal…
- Trial name
- BISER (NCT02268006)
- Testing
- IMRT-SIB, Capecitabine, Surgery
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- Institute of Oncology Ljubljana
CRC, Colorectal Cancer
An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS…
- Trial name
- NCT06985316
- Testing
- Tunlametinib combined with Fruquintinib
- Volunteers
- 34 people
- Sponsor
- Liu Huang
Colorectal Adenocarcinoma, RAS Wild Type
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally…
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT02292758
- Testing
- Bevacizumab, Cetuximab, Irinotecan
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00513266
- Testing
- bevacizumab, cetuximab, fluorouracil
- Where
- 4 sites in Switzerland
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Colorectal Cancer
Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients
The study aims to identify the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with local advanced colorectal cancer.
- Trial name
- NCT02415829
- Testing
- capecitabine plus oxaliplatin
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer (CRC)
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.
- Trial name
- NCT04627142
- Testing
- BI 1701963, Camptosar®
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Metastatic Colorectal Cancer
Study of IMC-11F8 in Participants With Colorectal Cancer
The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).
- Trial name
- NCT00835185
- Testing
- IMC-11F8 (necitumumab), Oxaliplatin, Folinic acid (FA)
- Where
- 5 sites in Belgium, Spain
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Chemotherapy Effect
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
This study is a prospective, randomized, comparative clinical trial conducted by Wuhan Union Hospital and aim to compare the therapeutic effects of Mitomycin and Lobaplatin in the treatment of advanced colorectal cancer patients…
- Conditions
- Colorectal Cancer, Chemotherapy Effect, Surgery, Metastasis
- Trial name
- WUHIPEC02 (NCT04845490)
- Testing
- Mitomycin, Lobaplatin
- Volunteers
- 201 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Solid Tumor, Adult, Colorectal Cancer
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma
- Trial name
- NCT06270082
- Testing
- IK-595
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- Ikena Oncology
Pelvic Exenteration, Advanced Pelvic Malignancy
A Contemporary Review of Surgical Approaches in Pelvic Exenterative Surgery
Minimally-invasive surgery (MIS) techniques have revolutionised the approach to rectal cancer surgery. With increasing experience, surgeons have began to utilise these platforms increasingly in the context of pelvic exenteration…
- Conditions
- Pelvic Exenteration, Advanced Pelvic Malignancy, Locally Advanced Rectal Cancer
- Trial name
- NCT04948762
- Where
- Ireland
- Volunteers
- 1,000 people
- Sponsor
- St Vincent's University Hospital, Ireland
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00027729
- Testing
- etaracizumab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Cancer
Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer
RATIONALE: Studying samples of tissue in the laboratory from patients who received cetuximab may help doctors understand and predict how well patients will respond to treatment.
- Trial name
- NCT01243372
- Testing
- mutation analysis, laboratory biomarker analysis
- Volunteers
- 1,142 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Neoplasm
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
- Trial name
- NCT03384940
- Testing
- DS-8201a
- Where
- 25 sites in United States, Italy and 3 more
- Volunteers
- 86 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Colorectal Cancer Stage IV
PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment
The purpose of this study is to test whether an early metabolic response, measured by PET/CT scan after the first cycle of chemotherapy, is able to predict which patients with advanced CRC have a better prognosis.
- Trial name
- PETRA2 - CRC (NCT02618850)
- Testing
- PET/CT, first-line chemotherapy
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- National Cancer Institute, Naples
Adenocarcinoma of the Rectum
Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
This study compares two standard radiotherapy approaches (short-course vs. long-course) given before surgery in patients with locally advanced rectal cancer.
- Trial name
- SHOOL (NCT07258797)
- Testing
- SCRT : 25 Gy in 5 fractions over 1 week to the pelvis using IGRT technique, LCRT + Consolidation Chemotherapy
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Rajiv Gandhi Cancer Institute & Research Center, India
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study of IOV-5001 in Adults With Advanced Solid Tumors
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
- Trial name
- NCT07743723
- Testing
- IOV-5001
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Iovance Biotherapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.